agilon health (AGL) Company Report

agilon health has initiated a significant transformation for 2026, projecting $125 million incremental benefit from contracting resets and $500 million incremental benefit from rate changes, alongside an anticipated 7% net cost trend.
The company ended 2025 with $285 million in cash and investments and $91 million in ACO cash, expecting to conclude 2026 with at least $125 million of cash on hand and targeting free cash flow break-even in 2027.
Operational enhancements include a strengthened financial data pipeline and the implementation of generative AI to improve RAF projections. The heart failure clinical pathway, now in 90% of markets, has reduced inpatient diagnoses from 25% in 2024 to less than 5% in 2025.
Successful contracting efforts led to an incremental percentage of premium, improved quality incentives, and decreased Part D exposure to under 15%. The company is also aggressively managing its physician networks, yielding meaningful value creation in markets like Michigan.

2 days ago

Transcript

agilon health Discusses 2026 Outlook, Clinical Pathways, and Cash Flow

AGL

Guidance Update

New Projects/Investments

Revenue Acceleration/Inflection

agilon health has initiated a transformation for 2026, projecting $125 million in incremental benefit from reset contracting and an additional $500 million in incremental benefit from rate changes. The estimated net cost trend for 2026 is about 7%.
The company has significantly improved visibility into RAF scores, now having a 99+% correlation with validated HCC codes, and anticipates a much smoother and earlier reconciliation process, potentially by Q2.
Clinical pathways, such as the heart failure program implemented in 90% of markets, have shown positive outcomes, including reducing inpatient diagnoses from 25% in 2024 to less than 5% in 2025 and lowering heart failure readmission rates below 10%. Dementia and COPD pathways are expected to be live in 70%+ of markets by the end of Q2.
agilon health ended 2025 with $285 million of cash and investments and $91 million of ACO cash, expecting to end 2026 with at least $125 million of cash on hand. The company believes there is a path to achieving free cash flow break-even or better in 2027.

2 days ago

Transcript

agilon health Provides 2026 Outlook and Operational Updates

AGL

Guidance Update

New Projects/Investments

Revenue Acceleration/Inflection

agilon health anticipates significant financial benefits in 2026, including $125 million in incremental benefit from contract resets and $500 million in incremental benefit from rate, with an estimated net cost trend of 7%.
The company expects approximately $22 million in benefit from its Burden of Illness program, driven by enhancements in data pipelines, AI algorithms, and clinical pathways. The heart failure pathway, implemented in 90% of markets, has notably reduced inpatient diagnoses from 25% in 2024 to less than 5% in 2025 and lowered readmission rates below 10%.
Visibility into RAF scores has significantly improved, with the data pipeline showing a 99+% correlation to midyear and final scores, leading to greater predictability and earlier reconciliation visibility.
agilon health ended 2025 with $285 million in cash and investments and $91 million in ACO cash, projecting to end 2026 with at least $125 million cash on hand. The company sees a path to free cash flow break-even or better in 2027 and potential for balanced membership growth.

2 days ago

Transcript

agilon health Provides Update on 2026 Profitability Initiatives and Q4 2025 Trends

AGL

Guidance Update

New Projects/Investments

Demand Weakening

agilon health reported a full-year cost trend of 6.5% for 2025, with the fourth quarter's cost trend estimated at 7.2% due to $6.5 million in unique inpatient cases in the third quarter.
The company is targeting break-even Adjusted EBITDA at the midpoint for 2026, supported by $125 million in medical margin improvement from disciplined contracting, $35 million in administrative cost reduction, and an expected 40 basis point year-over-year improvement in risk adjustment.
agilon health ended 2025 with over $60 million more cash than anticipated and projects an end-of-year cash balance of $125 million for 2026, an increase from its previous guide of $100 million.
The company has 85% of its members on an enhanced data pipeline, which provides new capabilities such as calculating member-level risk scores and January paid premiums, improving visibility into medical expenses.

Mar 2, 2026, 3:30 PM

Transcript

agilon health Discusses Q4 2025 Performance and 2026 Outlook

AGL

Guidance Update

Demand Weakening

New Projects/Investments

agilon health reported Q4 2025 cost trends increased to 6.5% for the full year, with Q3 trends at 7.2% driven by unique inpatient cases totaling over $6.5 million.
The company projects a break-even adjusted EBITDA at the midpoint for 2026, driven by $125 million in medical margin improvement from contracting, a 40 basis point year-over-year improvement in risk adjustment, and $35 million in administrative cost reductions.
agilon health anticipates an end-of-year cash balance of $125 million for 2026, an increase from the previous guidance of $100 million.
The company expects its membership to be 430,000 for 2026, a decrease from over half a million members at the end of 2025, as it right-sizes its cost structure.
Operational advancements include 85% of members now on an enhanced data pipeline for improved risk score calculation and the network-wide rollout of clinical programs for COPD and dementia in 2026.

Mar 2, 2026, 3:30 PM

Transcript

agilon health Discusses Q4 2025 Performance and 2026 Outlook

AGL

Guidance Update

New Projects/Investments

Demand Weakening

agilon health reported Q4 2025 cost trends at 6.5% for the full year, with Q3 at 7.2% due to unique inpatient cases totaling over $6.5 million.
The company is targeting break-even Adjusted EBITDA at the midpoint for 2026, driven by a 9+% effective growth rate from the final benchmark rate, over $125 million in medical margin improvement from disciplined contracting, 40 basis points year-over-year improvement in risk adjustment, and $35 million in overhead cost reduction.
The 2026 cost trend assumption is 7.5% gross and 7% net, reflecting a continuation of elevated trends seen in 2023-2025, particularly in inpatient and Part B (oncology) costs.
agilon health ended 2025 with a cash balance over $60 million better than anticipated and projects an end-of-year cash balance of $125 million for 2026, supported by a renewed credit facility.
The company has 85% of its members on an enhanced data pipeline, enabling member-level risk score calculation, and is rolling out new clinical programs for COPD and dementia in 2026.

Mar 2, 2026, 3:30 PM

Transcript

agilon health Reports Q4 and Full-Year 2025 Results, Provides 2026 Guidance

AGL

Earnings

Guidance Update

Cost Reductions

For the full year 2025, agilon health reported revenue of $5.93 billion, a negative medical margin of $57 million, and negative adjusted EBITDA of $296 million.
The company provided 2026 guidance, projecting revenue between $5.41 billion and $5.58 billion, a medical margin of $325 million, and breakeven adjusted EBITDA at the midpoint.
Year-end 2026 membership is expected to be 525,000-540,000 members, with Medicare Advantage membership estimated at 430,000, reflecting a disciplined contracting approach that led to exiting unprofitable payer contracts and a reduction of 50,000 Medicare Advantage members.
In 2025, the company executed $35 million in operating cost reductions and advanced clinical pathways and data capabilities, which are expected to contribute over $625 million in incremental medical margin value in 2026.
While acknowledging a lower-than-expected rate increase in CMS's Advance Notice for 2027, agilon health believes its clinically focused programs and model will help mitigate the impact.

Feb 25, 2026, 9:30 PM

Transcript

agilon health Reports Q4 and Full Year 2025 Results, Provides 2026 Guidance

AGL

Earnings

Guidance Update

New Projects/Investments

For the full year 2025, agilon health reported total revenue of $5.93 billion, a negative medical margin of $57 million, and negative adjusted EBITDA of $296 million.
The company provided 2026 guidance, expecting revenue between $5.41 billion and $5.58 billion, medical margin of $300 million to $350 million, and adjusted EBITDA ranging from -$15 million to +$15 million (breakeven at midpoint).
agilon health projects year-end membership for 2026 to be 525,000-540,000 members, including an estimated 430,000 Medicare Advantage members, a reduction attributed to a disciplined approach of exiting unprofitable payer contracts.
Strategic actions in 2025 included $35 million in operating cost reductions, strengthening financial data pipelines, and advancing clinical pathways, all aimed at improving profitability and managing elevated cost trends, which are assumed at 7.5% gross and 7% net for 2026.

Feb 25, 2026, 9:30 PM

Transcript

AGL reports Q4 and FY 2025 results and provides 2026 financial outlook

AGL

Earnings

Guidance Update

For Q4 2025, agilon health reported Total Revenues of $1,569 million, a Net Loss of $189 million, and Adjusted EBITDA of ($142 million). For the full year 2025, Total Revenues were $5,933 million, with a Net Loss of $391 million and Adjusted EBITDA of ($296 million).
The company provided a 2026 financial outlook, projecting Total Revenues between $5,410 million and $5,580 million, Medical Margin between $300 million and $350 million, and Adjusted EBITDA between ($15) million and $15 million for the full year. Total members live on platform are expected to be 525,000 to 540,000 for FY 2026.
agilon health anticipates improved 2026 performance driven by reduced operating expenses of $35 million, a strong balance sheet with ~$285 million in cash & short-term investments, and a structurally stronger earnings base from business transformation initiatives, including an improved rate environment and disciplined re-contracting. The company expects a $296 million improvement to breakeven Adjusted EBITDA for 2026.

Feb 25, 2026, 9:30 PM

Presentation

agilon health Reports Q4 and Full Year 2025 Results, Provides 2026 Guidance

AGL

Earnings

Guidance Update

New Projects/Investments

agilon health reported full year 2025 revenue of $5.93 billion, with a negative medical margin of $57 million and negative adjusted EBITDA of $296 million.
For 2026, the company projects revenue between $5.41 billion and $5.58 billion, with an expected medical margin of $325 million and breakeven adjusted EBITDA, driven by a focus on profitability and disciplined contracting.
The company's 2026 Medicare Advantage membership is expected to be 430,000, a reduction of 50,000 members due to exiting unprofitable payer contracts, and anticipates elevated net cost trends of approximately 7%.
agilon health ended Q4 2025 with $285 million in cash and marketable securities and expects to end 2026 with at least $125 million of cash on hand.

Feb 25, 2026, 9:30 PM

Transcript

Earnings Transcripts

Quarterly earnings call transcripts for agilon health.

Q4 2025

Feb 25, 2026

→

Q3 2025

Nov 4, 2025

→

Q2 2025

Aug 4, 2025

→

View All Transcripts

Ask Fintool AI Agent

Get instant answers from SEC filings, earnings calls & more

What are agilon health's strategic priorities?How is agilon health positioned vs competitors?How did agilon health do last quarter?

agilon health (AGL)

Analyst Earnings Quarterly Reports

Q3 2025

Q2 2025

Q1 2025

Q4 2024

Executives

Ben Shaker

Denise Zamore

Girish Venkatachaliah

Heidi Hittner

Jeffrey Schwaneke

Karthik Rao

Ron Williams

Board Members

Diana McKenzie

Karen McLoughlin

Ravi Sachdev

Sharad Mansukani

Silvana Battaglia

William Wulf

Analyst Coverage

Justin Lake

Ryan Langston

Jack Slevin

George Hill

Jailendra Singh

Michael Ha

Andrew Mok

Craig Jones

Daniel Grosslight

Elizabeth Anderson

Lisa Gill

Matthew Shea

Stephen Baxter

Adam Ron

Amir Farahani

Benjamin Mayo

Jenny Shen

Liz

Luis

Matthew Wagner

Ryan Daniels

Stephen Baxter

David Larsen

Eduardo Ron

Hua Ha

Joanna Gajuk

Lance Wilkes

Olivier

Thomas Walsh

Latest news

Earnings Transcripts

Q4 2025

Q3 2025

Q2 2025

Ask Fintool AI Agent